1 / 78

Faculty

Faculty. Panelists. Disclosures. Disclosures (cont). Target Audience and Learning Objectives. Metastatic Colorectal Cancer (mCRC). mCRC: Resectable. mCRC: (R)evolution. mCRC: (R)evolution (cont). mCRC: Approved/Investigational Drugs. mCRC: Past, Present, and Future.

wing-richards
Download Presentation

Faculty

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Faculty

  2. Panelists

  3. Disclosures

  4. Disclosures (cont)

  5. Target Audience and Learning Objectives

  6. Metastatic Colorectal Cancer (mCRC)

  7. mCRC: Resectable

  8. mCRC: (R)evolution

  9. mCRC: (R)evolution (cont)

  10. mCRC: Approved/Investigational Drugs

  11. mCRC: Past, Present, and Future

  12. mCRC: Targeted Therapy — Anti-Angiogenic

  13. mCRC: Targeted Therapy — Anti-EGFR Biomarkers

  14. mCRC: RAS Mutation Status

  15. mCRC: Case Example

  16. mCRC: Chemotherapy for Diffuse Metastatic Disease

  17. mCRC: Chemotherapy for Diffuse Metastatic Disease cont

  18. mCRC: Current Options for Addition of Biological Agent

  19. mCRC: Treatment Options According to Clinical Criteria

  20. mCRC: Which Frontline Regimen Should Be Used?

  21. mCRC: Treatment Strategy

  22. mCRC: Case Example: Progressing Disease With First- and Second-line Therapy

  23. Angiogenesis and Cancer: Rebound Effect

  24. Anti-Angiogenesis and mCRC: Beyond Progression

  25. Anti-angiogenesis and mCRC: Beyond Progression (Preclinical Studies)

  26. Anti-angiogenesis and mCRC: Beyond Progression(preclinical data)

  27. Anti-angiogenesis and mCRC: Beyond Progression (Clinical Data)

  28. mCRC Strategies: Consolidation/Maintenance Treatment

  29. Consolidation/Maintenance Treatment — Timing and Efficacy

  30. Consolidation/Maintenance Treatment — CAIRO3

  31. Biomarker Status Over Time

  32. mCRC: Serial Biomarker Testing

  33. mCRC: Metabolic Imaging

  34. mCRC: Liquid Biopsy - Following Changes in Genomic Status

  35. mCRC: Dynamic Biomarker Study (UK)

  36. Team Approach to Oncologic Therapy

  37. Case Presentation, Part 1

  38. Patient Case, Part 1: History

  39. Patient Case, Part 1: Presentation and Findings

  40. Patient Case, Part 1: Imaging and Laboratory Findings

  41. Patient Case, Part 1: Clinical Considerations

  42. Patient Case, Part 1: Treatment Options

  43. Patient Case, Part 1: Initial Treatment and Instructions

  44. Patient Case, Part 1: Response to Treatment

  45. Patient Case, Part 1: Progression on Maintenance Therapy

  46. Discussion (Part 1)Fortunato Ciardiello, MD; Marc Peeters, MD, PhD

  47. Case Presentation, Part 2

  48. Patient Case, Part 2: First Relapse

More Related